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Acute Myeloid Leukemia: The 
Race to Diagnosis and 
Treatment! 
Leila Khaddour, MD, Vijaya Donthireddy, MD, Vrushali Dabak, MD,
Hematology and Oncology Department
Henry Ford Hospital
Introduction 
Acute myeloid leukemia (AML) is the most common acute 
leukemia affecting adults and one of the hematologic 
emergencies that require prompt treatment.
AML is typically categorized based on combinations of mutations 
and/or altered expression of certain genes
FLT3 mutation is associated poor prognosis and early relapse in 
AML. Midostaurin is a multi-kinase inhibitor, when added to 
induction 7+3 chemotherapy starting at day 8-21, improves the 
response rate and disease-free survival.
Genetic profiling should be performed on newly diagnosed 
patients with AML. Particularly it is important to get the result of 
FLT3 mutation before day 8 of induction. 
Purpose 
 Evaluate our institution efficiency obtaining the appropriate 
molecular studies in AML cases at the time of diagnosis.
 Time is very sensitive in the management of acute myeloid 
leukemia. Induction chemotherapy should be administered 
once morphologic diagnosis is made and usually before 
the genetic testing results are available
 It requires high collaboration between the hematologist, 
pathologist and laboratory staff.
 Once molecular studies are available, the need for targeted 
therapy will be determined. Next generation sequencing (NGS) 
is fast and comprehensive method in molecular analysis
Methods 
• The electronic medical records were reviewed for all AML cases 
diagnosed between January 2016 and December 2018. 
• Quality measures were defined:
1. Average duration between bone marrow biopsy and the morphology 
results.
2. Average duration between bone marrow biopsy and date of molecular 
order.
3. Average duration between molecular order and available results.
4. Average duration between induction date 
and the administering Midostaurin if needed for FLT3 mutated cases.
RESULTS 
Between January 2016 and December 
2018, 86 AML cases were diagnosed and 
treated in out institution. 76% of cases 
were diagnosed in the hospital while in 
24% diagnosis was in bone marrow biopsy 
obtained in the clinic.
All patients were admitted to the hospital.
Morphology results were reported on 
average of 3 and 4.2 days in the inpatient 
and outpatient setting respectively
Type of 
Molecular 
Study
 Molecular studies were obtained in 65 cases
• NGS panel in 19 cases-
• De-novo AML in 22 cases
• Custom in 24 cases
Molecular Study Results Time Range
FLT3 
Mutation 
Positive
 The average time between induction and FLT3 mutation results is 12.38 
days
 The average delay in administering the target therapy(midostaurin) is 
4.38 days
Discussion
 Our institution experience has improved in the past 3 years 
increasing the rate of ordering molecular studies for newly diagnosed 
AML.
 NGS-54 gene panel is an institutional comprehensive panel includes 
all gene of interest and includes FLT3 mutation. There has been an 
increasing rate in ordering this panel; 9 cases in 2017 to 17 cases in 
2018 
 FLT3 mutation analysis was included in a total of 51 patients over 3 
years. However, in 2018, It was included in 
29/31 cases which correlates with the clinical use of FLT3 inhibitor
Discussion 
 In cases with FLT3 mutation, there is an average 4.38-day delay in 
administering targeted therapy due to the delay ordering and getting 
the results in appropriate time manner.
 We suggested the following changes: 
1. Standardize the order by obtaining NGS-54 gene panel on all Leukemia 
cases at the time of obtaining the bone marrow biopsy
2. Ongoing discussion between the hematology department 
and pathology department to improve the communication and ordering 
pathways
2. Address the efficacy of these measures in new AML cases diagnosed in 2019.
Conslusion
 Obtaining the genetic profiling is very 
important prognostic and therapeutic measure in newly 
diagnosed AML. The presence of FLT3 mutation convey poor 
prognosis. FLT3 inhibitor, Midostaurin, when added on Day 8 of 
induction improves the outcomes.
 In our institution experience, there is an average delay of 4.38 days 
in administering midostaurin in FLT3 mutated AML cases.
 We believe that standardizing the ordering 
process with obtaining NGS panel on all new leukemia cases 
will improve and expedite getting the results in appropriate manner

